ELI LILLY & Co is 689.8x more valuable than AbCellera Biologics Inc. by market capitalization ($1.072 T vs $1.55 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ABCL | LLY |
|---|---|---|
| Market cap | $1.55 B | $1.072 T |
| US-listed rank | #2293 | #10 |
| Revenue (latest FY) | $75.13M | $65.18B |
| Net income (latest FY) | -$146.41M | $20.64B |
| Net margin | -194.9% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 297 | 989 |
ELI LILLY & Co is 689.8x more valuable than AbCellera Biologics Inc. by market capitalization ($1.072 T vs $1.55 B).
In their latest fiscal years, AbCellera Biologics Inc. reported $75.13M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: AbCellera Biologics Inc. and ELI LILLY & Co, or browse the full rankings.